CN1282471C - 治疗过敏性皮肤病的药物 - Google Patents
治疗过敏性皮肤病的药物 Download PDFInfo
- Publication number
- CN1282471C CN1282471C CN 200410040607 CN200410040607A CN1282471C CN 1282471 C CN1282471 C CN 1282471C CN 200410040607 CN200410040607 CN 200410040607 CN 200410040607 A CN200410040607 A CN 200410040607A CN 1282471 C CN1282471 C CN 1282471C
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- medicine
- allergic
- skin diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 208000017520 skin disease Diseases 0.000 title claims abstract description 23
- 208000010668 atopic eczema Diseases 0.000 title abstract description 29
- 230000000172 allergic effect Effects 0.000 title abstract description 23
- 229940079593 drug Drugs 0.000 title description 30
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 15
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 15
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 13
- 241000246044 Sophora flavescens Species 0.000 claims abstract description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 10
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 10
- 229940010454 licorice Drugs 0.000 claims abstract description 10
- 229930182490 saponin Natural products 0.000 claims abstract description 10
- 150000007949 saponins Chemical class 0.000 claims abstract description 10
- 235000017709 saponins Nutrition 0.000 claims abstract description 10
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 4
- 244000132619 red sage Species 0.000 claims description 14
- 241000202807 Glycyrrhiza Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 56
- 230000000694 effects Effects 0.000 description 52
- 208000003251 Pruritus Diseases 0.000 description 28
- 230000007803 itching Effects 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 21
- 206010020751 Hypersensitivity Diseases 0.000 description 18
- 201000004624 Dermatitis Diseases 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 206010040882 skin lesion Diseases 0.000 description 12
- 231100000444 skin lesion Toxicity 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- 230000007815 allergy Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000037380 skin damage Effects 0.000 description 7
- 206010014025 Ear swelling Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000219304 Portulacaceae Species 0.000 description 6
- 208000030961 allergic reaction Diseases 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 6
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 6
- 229960003291 chlorphenamine Drugs 0.000 description 6
- 238000005352 clarification Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000037257 muscle growth Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 240000001307 Myosotis scorpioides Species 0.000 description 5
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008395 clarifying agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000005951 type IV hypersensitivity Effects 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 229960004754 astemizole Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 206010037083 Prurigo Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 102000011759 adducin Human genes 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- -1 dry Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010051837 Skin induration Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008921 jie er yin Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004096 non-sedating histamine H1 antagonist Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
| 组别 | n | 剂量(g/kg) | 吸光度(A) | 抑制率(%) |
| 空白对照扑尔敏常规剂量高剂量 | 14131311 | 等容量NS0.00434102 | 0.126±0.0250.056±0.016**0.078±0.014**0.072±0.018** | 55.662.058.1 |
| 组别 | n | 剂量(g/kg) | 吸光度(A) | 抑制率(%) |
| 空白对照扑尔敏常规剂量高剂量 | 10101010 | 等容量NS0.00434102 | 0.175±0.0520.052±0.015**0.129±0.016*0.106±0.014** | 69.030.140.6 |
| 组别 | n | 剂量(g/kg) | 耳肿胀度 |
| 空白对照醋酸泼尼松常规剂量高剂量 | 16161616 | 等容量NS0.00534102 | 4.058±0.7971.388±0.712**2.822±0.795**2.544±1.275** |
| 组别 | n | 剂量(g/kg) | 搔痒次数 | 搔痒持续时间 |
| 空白对照扑尔敏常规剂量高剂量 | 12141214 | 等容量NS0.00434102 | 31.7±12.515.6±8.5**19.9±6.8**16.7±5.4** | 165.8±48.334.6±19.9**60.1±25.0**51.3±18.6* |
| 组别 | n | 剂量(g/kg) | 吸光度(A) | 抑制率(%) |
| 空白对照扑尔敏常规剂量高剂量 | 16151414 | 等容量NS0.00434102 | 0.496±0.1210.130±0.063**0.213±0.078**0.255±0.104** | 73.857.048.6 |
| 组别 | n | 剂量(g/kg) | 耳肿胀度 |
| 空白对照醋酸泼尼松常规剂量高剂量 | 10101010 | 等容量NS0.00534102 | 15.4±1.548.2±0.51**12.3±2.37**10.1±1.56** |
| 组别 | n | 剂量(g/kg) | 脱颗粒率(%) | 抑制率(%) |
| 空白对照色甘酸钠常规剂量高剂量 | 10101010 | 等容量NS0.02523.470.2 | 85.0±4.530.2±6.4**67.0±7.6**53.8±8.8** | 64.421.236.6 |
| 组别 | n | 剂量(g/kg) | IgE值(iv/ml) |
| 空白对照模型对照常规剂量高剂量 | 10101010 | 等容量NS等容量NS20.1560.45 | 50.5±4.390.9±12.9**68.4±5.8*65.2±8.9* |
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040607 CN1282471C (zh) | 2004-09-02 | 2004-09-02 | 治疗过敏性皮肤病的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040607 CN1282471C (zh) | 2004-09-02 | 2004-09-02 | 治疗过敏性皮肤病的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1596953A CN1596953A (zh) | 2005-03-23 |
| CN1282471C true CN1282471C (zh) | 2006-11-01 |
Family
ID=34664732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410040607 Expired - Fee Related CN1282471C (zh) | 2004-09-02 | 2004-09-02 | 治疗过敏性皮肤病的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1282471C (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107296909A (zh) * | 2017-06-14 | 2017-10-27 | 合肥丰瑞隆生物科技有限公司 | 一种治疗过敏性皮炎的中药 |
| CN114886959B (zh) * | 2022-07-13 | 2022-09-30 | 云南琼月企业管理有限公司 | 一种药物组合物及其制剂和应用 |
-
2004
- 2004-09-02 CN CN 200410040607 patent/CN1282471C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1596953A (zh) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (zh) | 一种治疗由脏腑病所致眼病的药物 | |
| CN104068279B (zh) | 一种含有中药添加剂的鳗鱼饲料及其制备方法 | |
| CN101062289A (zh) | 治疗痛风的外用药物组合物 | |
| CN102716395B (zh) | 用于皮肤疾病的中药喷雾剂 | |
| CN102716394B (zh) | 用于皮肤疾病的药物组合物 | |
| CN105616679A (zh) | 一种养血安神中药制剂及其制备方法 | |
| CN1282471C (zh) | 治疗过敏性皮肤病的药物 | |
| CN104000919B (zh) | 一种中药组合物 | |
| CN104225386A (zh) | 一种高效低毒的复方雷公藤凝胶膏及其制备方法 | |
| CN1251753C (zh) | 一种治疗乳腺增生病的外用药组合物及其制备方法 | |
| CN113144115A (zh) | 一种治疗寻常疣的中药组合物及其应用 | |
| CN107213250B (zh) | 一种用于防治类风湿关节炎的中药组合物及其制备方法 | |
| CN114617919B (zh) | 一种用于治疗湿疹或荨麻疹的组合物、其制备方法及制药用途 | |
| CN117653701B (zh) | 一种治疗男性性功能障碍的组合物 | |
| CN1850200A (zh) | 一种治疗口腔溃疡的中药外用药的配方 | |
| CN119633096B (zh) | 一种治疗痛风肿痛关节炎的外用中药组合物及其制备方法和应用 | |
| CN117045717B (zh) | 一种治疗湿疹的外用复方精油组合物及其制备方法 | |
| CN116036225B (zh) | 一种天然来源的治疗关节炎的外用药物组合物 | |
| CN105194676B (zh) | 一种治疗高脂血症的药物组合物及其制备方法 | |
| CN1824204A (zh) | 一种治疗急性痛风性关节炎的药物组合物及其制备方法 | |
| CN1281238C (zh) | 治疗末梢神经炎的外用药及其制备方法 | |
| CN1709312A (zh) | 治疗荨麻疹和皮肤瘙痒症的中药组合物及其制备方法 | |
| CN1947583A (zh) | 一种养颜健身的胶冻及其制备方法 | |
| CN107837315A (zh) | 一种治疗鹅掌风的中药组合物及其制备方法 | |
| CN1304043C (zh) | 龙鹤丹颗粒剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN COLLEGE OF TRADITIONAL CHINESE MEDICINE Free format text: FORMER OWNER: LI QINGSHENG Effective date: 20091127 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091127 Address after: 201, Shuangqiao Road, Kunming, Yunnan, China Patentee after: Yunnan University of Traditional Chinese Medicine Address before: 201, Shuangqiao Road, Kunming, Yunnan, China Patentee before: Li Qingsheng |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061101 Termination date: 20200902 |